Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2019-03-28
DOI
10.1080/2162402x.2019.1596006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
- (2018) Jacob P. van Vloten et al. JOURNAL OF IMMUNOLOGY
- Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition
- (2018) Mohammed Selman et al. Science Translational Medicine
- Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
- (2018) Shashi Gujar et al. TRENDS IN IMMUNOLOGY
- Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy
- (2018) Michael Phan et al. ACS Infectious Diseases
- Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
- (2018) Jonathan G. Pol et al. OncoImmunology
- Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
- (2017) Bernd Heinrich et al. OncoTargets and Therapy
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Immune System, Friend or Foe of Oncolytic Virotherapy?
- (2017) Anna C. Filley et al. Frontiers in Oncology
- Talimogene Laherparepvec for the Treatment of Advanced Melanoma
- (2016) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Oncolytic viruses as immunotherapy: progress and remaining challenges
- (2016) Laure Aurelian OncoTargets and Therapy
- The role of oncolytic virus immunotherapies to subvert cancer immune evasion
- (2015) Samuel T Workenhe et al. Future Oncology
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Theoretical study of the dimerization of aqueous beryllium cations
- (2015) Xiaoyan Jin et al. JOURNAL OF MOLECULAR MODELING
- Membrane Perturbation-Associated Ca2+Signaling and Incoming Genome Sensing Are Required for the Host Response to Low-Level Enveloped Virus Particle Entry
- (2015) David N. Hare et al. JOURNAL OF VIROLOGY
- Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
- (2015) Norman Woller et al. MOLECULAR THERAPY
- Control of adaptive immunity by the innate immune system
- (2015) Akiko Iwasaki et al. NATURE IMMUNOLOGY
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Trial Watch—Oncolytic viruses and cancer therapy
- (2015) Jonathan Pol et al. OncoImmunology
- Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
- (2015) Jennifer L Leddon et al. Molecular Therapy-Oncolytics
- Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
- (2014) E. Galanis et al. CANCER RESEARCH
- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
- (2014) Shashi A. Gujar et al. Frontiers in Oncology
- Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype
- (2013) B P Cuddington et al. CANCER GENE THERAPY
- Molecular mechanisms of ATP secretion during immunogenic cell death
- (2013) I Martins et al. CELL DEATH AND DIFFERENTIATION
- PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice
- (2013) M. Z. Tesfay et al. JOURNAL OF VIROLOGY
- Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation
- (2013) Shashi Gujar et al. MOLECULAR THERAPY
- Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies
- (2013) Samuel T Workenhe et al. MOLECULAR THERAPY
- Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy
- (2013) Samuel T Workenhe et al. MOLECULAR THERAPY
- Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses
- (2013) Fernando A. Angarita et al. TRENDS IN MOLECULAR MEDICINE
- Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
- (2012) Dmitriy Zamarin et al. Future Microbiology
- The oncolytic herpes simplex virus vector G47Δ effectively targets breast cancer stem cells
- (2012) WEIGEN ZENG et al. ONCOLOGY REPORTS
- Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
- (2012) Allison J Black et al. Expert Review of Clinical Pharmacology
- Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming
- (2011) Lynette Steele et al. Molecular Cancer
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy
- (2010) Paul T Sobol et al. MOLECULAR THERAPY
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma
- (2009) F Galivo et al. GENE THERAPY
- The HSV-2 mutant ΔPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins
- (2009) A G Colunga et al. GENE THERAPY
- The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon
- (2009) Robin J. Prestwich et al. HUMAN GENE THERAPY
- Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus
- (2009) Konstantin Doronin et al. HUMAN GENE THERAPY
- Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
- (2008) Roberto Cattaneo et al. NATURE REVIEWS MICROBIOLOGY
- Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
- (2008) A L Fridman et al. ONCOGENE
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
- (2008) T. L.-A. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now